{"id":"anastozole-arimidex","safety":{"commonSideEffects":[{"rate":"36","effect":"Hot flashes"},{"rate":"15-26","effect":"Arthralgia/joint pain"},{"rate":"19","effect":"Fatigue"},{"rate":"13","effect":"Headache"},{"rate":"2-5","effect":"Vaginal dryness"},{"rate":null,"effect":"Osteoporosis/bone loss"},{"rate":null,"effect":"Elevated cholesterol"}]},"_chembl":{"chemblId":"CHEMBL1399","moleculeType":"Small molecule","molecularWeight":"293.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anastrozole selectively inhibits the aromatase enzyme, which catalyzes the final step of estrogen synthesis in peripheral tissues. By reducing circulating estrogen levels, it deprives estrogen-dependent breast cancer cells of growth signals. This mechanism is particularly effective in postmenopausal women where aromatase is the primary source of estrogen production.","oneSentence":"Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:35.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women"},{"name":"First-line treatment of advanced breast cancer in postmenopausal women"},{"name":"Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer"}]},"trialDetails":[{"nctId":"NCT00849030","phase":"PHASE3","title":"ATAC - Arimidex, Tamoxifen Alone or in Combination","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1996-07","conditions":"Breast Cancer","enrollment":9358}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arimidex"],"phase":"phase_3","status":"active","brandName":"Anastozole (Arimidex)","genericName":"Anastozole (Arimidex)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. Used for Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women, First-line treatment of advanced breast cancer in postmenopausal women, Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}